The U.S. Food and Drug Administration has approved Ruzurgi (amifampridine) tablets to treat children with a rare autoimmune disorder known as Lambert-Eaton myasthenic syndrome (LEMS). The drug is approved for treating patients aged 6 to 17 years.
Lambert-Eaton myasthenic syndrome affects the muscle as the immune system attacks one’s own neuromuscular junction and interferes with the ability of nerve cells to send signals to muscle cells.
Ruzurgi is the first treatment to be sanctioned for children with LEMS. The approval was granted to Jacobus Pharmaceutical Company Inc. this week.